Navigation Links
Odyssey Thera, Inc. Announces New Equity Financing and Initiation of Research Contract with Merck

SAN RAMON, Calif., Feb. 14, 2013 /PRNewswire/ -- Odyssey Thera, Inc., a privately held biotechnology company, announced today a new equity financing and the initiation of a research service contract with Merck, known as MSD outside the U.S. and Canada.

Additional participants in this financing include HBM Partners, Burrill & Company, and Lonza.  The financing, comprising new funds and debt conversion, totals $2.8M. These funds will be used to support continued advancement and expanded commercialization of Odyssey Thera's technologies and products.

"The support from current and new investors will expedite commercialization of Odyssey Thera technologies," said Dr. John K. Westwick , President and CEO of Odyssey Thera. "We look forward to supporting Merck and other leading discovery and development programs with these validated capabilities."   

About Odyssey Thera, Inc.

Odyssey Thera was founded over ten years ago with the goal of transforming drug discovery through deep cellular analysis. Odyssey's patented technologies measure disease-relevant pathway activity within living human cells. Unprecedented throughput and breadth of high-content assays enables assessment of key signaling nodes as well as the cellular system, allowing for rapid identification of drug candidates with optimal efficacy and safety profiles. The Company's leadership position in fundamental patents, technology, and know-how relating to cellular analysis has led to alliances with Pfizer, Abbott, Merck, the U.S. EPA, and others. To learn more about Odyssey Thera, please visit

SOURCE Odyssey Thera, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. HKTU Announces Development of a New Male Enhancement Supplement
2. STAAR Surgical Announces Fourth Quarter 2012 Results Release Date And Conference Call And Webcast
3. United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
4. Breckenridge Announces Approval for Pioglitazone Hydrochloride tablets
5. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
6. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
7. Xenon Announces Appointment of EVP, Research & Development
8. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
9. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
10. OrbusNeich Announces Favorable Ruling From the European Patent Office
11. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... and TELTOW, Germany , December ... (SMI) , a leading global manufacturer of eye and ... has included SMI remote eye trackers as a ... healthcare providers assess concussions, eye sight, and medical and ... -oem technology is part of SMI,s mass-market-ready eye tracking ...
(Date:12/1/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... 2016 as the ex-distribution date for Ampio,s previously announced ... Stock of Aytu BioScience, Inc. As announced, Ampio will ... every five (5) shares of Ampio Common Stock owned ... date will be January 4, 2016. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic ... addition to the devices for sale in the United States. Clarity is a ... 1064 nm Nd:YAG lasers, into a single platform that is easy to own and ...
(Date:12/1/2015)... ... ... With FCPX Overlay: Grit , users can apply a grit effect ... truly endless, all with a click of a mouse. Each user has full control ... of field and more, all within Final Cut Pro X. , With FCPX Overlay: ...
(Date:11/30/2015)... India (PRWEB) , ... November 30, 2015 , ... ... dental search engine optimization companies, announced today that it has officially launched a ... Third Molar SEO, explained that his company’s new website clearly outlines the benefits ...
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
Breaking Medicine News(10 mins):